Interview with Sabine Dandiguian, President, Janssen-Cilag France
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
The Winncare group is working with specialists in the (para)medical field to develop a range of medical equipment adapted for people in care, the elderly, disabled people and health and social care professionals. Their aim is to improve services and people’s quality of care and life by offering efficient and high quality products and services. Winncare has positioned itself to be in the market of preventative care, especially patients at risk of bedsores or loss of autonomy. Today the focus is on expanding its position throughout Europe. The objective of the company is to reach a turnover of 100 million Euros (USD 109 million) from their current revenues of 45 million Euros (USD 48 million) over the course of five years, primarily through organic growth as well as strategic acquisition.
Contact
Regus – Groupe Winncare
Bureaux 1507A11507B
La Grande Arche – Paroi Nord
90244 La Defense Cedex
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
See our Cookie Privacy Policy Here
